Abstract
MRSA infections, especially pneumonia have been associated with considerable morbidity and mortality and the management of MRSA infections is considered as an issue of high priority for scientific societies. Many studies which have been published during the last 10 years have provided evidence for MRSA pneumonia epidemiology, diagnosis and treatment. The main regime of antibiotic treatment recommended for MRSA pneumonia is either vancomycin or linezolid. Despite its pK/pD superiority over vancomycin, linezolid has to date failed to show clear advantage over vancomycin in recent clinical trials.
Keywords: Pneumonia, MRSA, Vancomycin, Linezolid, EPIDEMIOLOGY, Prognosis, healthcare associated (HCAP), ventilator associated (VAP), Etiological diagnosis, water-soluble drug
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
16